Show
Sort by
-
Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence : a prospective, randomized, multicenter phase II trial
-
Reply to J.-E. Bibault et al, B. Tombal, and C. Cattrini et al
-
Prediction of breast and prostate cancer risks in male BRCA1 and BRCA2 mutation carriers using polygenic risk scores
-
Distrust in the end-of-life care provided to a parent and long-term negative outcomes among bereaved adolescents : a population-based survey study
-
Immune cell profiling of melanoma metastases from patients treated with TriMixDC-MEL dendritic cell therapy in combination with ipilimumab
-
A NKG2D-based CAR-T therapy in a multinational phase I dose escalation and expansion study targeting multiple solid and hematologic tumor types
-
Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL)
-
Combined DNA-methylation intensity and clinical risk score to stratify patients for high-grade disease
-
Phase I study of mTORC1/2 inhibitor BI 860585 as single agent or with exemestane or paclitaxel in patients with advanced solid tumors
-
Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III FIRST trial